Pliant Therapeutics Inc
PLRX1.660USD
+0.080+5.06%
Market hours （ET）Quotes delayed by 15 min
101.90MMarket Cap
LossP/E TTM
More Details of Pliant Therapeutics Inc Company
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.
Company Info
Ticker SymbolPLRX
Company namePliant Therapeutics Inc
IPO dateJun 03, 2020
CEODr. Bernard J. Coulie, M.D., Ph.D.
Number of employees171
Security typeOrdinary Share
Fiscal year-endJun 03
Address331 Oyster Point Boulevard
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone16504816770
Websitehttps://pliantrx.com/
Ticker SymbolPLRX
IPO dateJun 03, 2020
CEODr. Bernard J. Coulie, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
705.63K
-8.97%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-68.53%
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Dr. Delphine Imbert, Ph.D.
Dr. Delphine Imbert, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
705.63K
-8.97%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-68.53%
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
9.77%
Deep Track Capital LP
8.80%
BlackRock Institutional Trust Company, N.A.
7.40%
The Vanguard Group, Inc.
4.89%
Cormorant Asset Management, LP
4.89%
Other
64.25%
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
9.77%
Deep Track Capital LP
8.80%
BlackRock Institutional Trust Company, N.A.
7.40%
The Vanguard Group, Inc.
4.89%
Cormorant Asset Management, LP
4.89%
Other
64.25%
Shareholder Types
Shareholders
Proportion
Hedge Fund
35.59%
Investment Advisor
28.68%
Investment Advisor/Hedge Fund
19.92%
Research Firm
5.73%
Venture Capital
4.24%
Individual Investor
3.04%
Family Office
0.87%
Bank and Trust
0.30%
Pension Fund
0.22%
Other
1.42%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
370
63.27M
103.07%
-13.14M
2025Q1
390
63.45M
103.37%
-12.99M
2024Q4
392
71.13M
116.20%
-8.66M
2024Q3
388
69.61M
114.50%
-7.63M
2024Q2
375
69.93M
115.87%
-7.66M
2024Q1
371
73.36M
121.74%
-3.24M
2023Q4
362
70.03M
116.83%
-95.89K
2023Q3
356
64.13M
107.25%
-2.06M
2023Q2
347
62.06M
104.99%
-496.00K
2023Q1
337
60.53M
102.92%
+8.55M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tang Capital Management, LLC
6.00M
9.77%
+6.00M
--
Mar 31, 2025
Deep Track Capital LP
5.40M
8.8%
-572.58K
-9.59%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.54M
7.4%
+52.45K
+1.17%
Mar 31, 2025
The Vanguard Group, Inc.
3.33M
5.42%
+105.82K
+3.29%
Mar 31, 2025
Cormorant Asset Management, LP
3.00M
4.89%
+3.00M
--
Mar 31, 2025
Blue Owl Capital Holdings LP
2.97M
4.84%
+200.00K
+7.22%
Mar 31, 2025
UBS Financial Services, Inc.
2.65M
4.31%
+2.02M
+321.08%
Mar 31, 2025
Woodline Partners LP
2.51M
4.1%
+2.39M
+1875.01%
Mar 31, 2025
Third Rock Ventures, LLC
2.13M
3.47%
--
--
Mar 31, 2025
Redmile Group, LLC
2.05M
3.35%
-841.92K
-29.08%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Vanguard US Value Factor ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
SPDR S&P Pharmaceuticals ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
View more
Vanguard US Value Factor ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
iShares Micro-Cap ETF
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
FlexShares Morningstar US Market Factor Tilt Index Fund
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
SPDR S&P Pharmaceuticals ETF
Proportion0%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
